

**TEST CHANGE**

**N-Telopeptide, Cross-Linked, Urine**

0070062, NTX

**Specimen Requirements:**

**Patient Preparation:** For monitoring therapy, a baseline specimen should be collected prior to initiation of therapy. Subsequent specimens for comparison should be collected at the same time of day as the baseline specimen.

**Collect:** Second-morning void or 24-hour urine. Refrigerate during collection. Collect without preservative.

**Specimen Preparation:** Transfer a 1 mL aliquot of urine from a well-mixed, second-morning void or 24-hour collection to an ARUP Standard Transport Tube. (Min: 0.5 mL)

**Transport Temperature:** Frozen.

**Unacceptable Conditions:** Specimens contaminated with blood or extensive hemolysis.

**Remarks:**

**Stability:** Ambient: 24 hours; Refrigerated: 1 week; Frozen: 4 weeks<sup>2</sup>  
years

**Methodology:** Quantitative Chemiluminescent Immunoassay

**Performed:** Tue-Sat

**Reported:** 1-4 days

**Note:**

**CPT Codes:** 82523

**New York DOH Approval Status:** This test is New York DOH approved.

**Interpretive Data:**

NTx Units = nM BCE/mM creatinine

A decrease of 30-40% from the NTx baseline after three months of therapy is a typical response to anti-resorptive therapy.

NTx = Cross-linked N-telopeptide of Type I Collagen

BCE = Bone Collagen Equivalent

**Reference Interval:**

Age	Male	Female
7-9 years	167-578 nM BCE/mM creatinine	201-626 nM BCE/mM creatinine
10-12 years	152-505 nM BCE/mM creatinine	173-728 nM BCE/mM creatinine
13-15 years	103-776 nM BCE/mM creatinine	38-515 nM BCE/mM creatinine
16-17 years	34-313 nM BCE/mM creatinine	20-144 nM BCE/mM creatinine
18 years and older	21-83 nM BCE/mM creatinine	
Premenopausal		17-94 nM BCE/mM creatinine
Postmenopausal		26-124 nM BCE/mM creatinine